"Sandoz Will be the Leading Biosimilar Drug Company in 2012, with Revenue of $308 Million" Predicts New Visiongain Report
A new report by Visiongain predicts that Sandoz will retain its position as the global leader in the biosimilar drugs market in 2012. In that year, its three follow-on biologics will achieve $308m in revenue. Combined revenue for the top three companies in that market will grow with a CAGR of close to 25% between 2011 and 2016. Those findings, and others, appear in Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022, published in 1st October 2012.
London, United Kingdom, October 07, 2012 --(PR.com)-- Visiongain’s analysis indicates that, in 2011, the top ten biosimilar drug manufacturers accounted for 54.8% of that market. Global generics manufacturers occupied three of the top four places in the ranking. Leading manufacturers based in India, China and South Korea were also among the top ten biosimilar manufacturers. All companies among the top 25 will experience revenue growth in the coming 10 years, although most will have market share fall.
Richard Lang, a pharmaceutical industry analyst for visiongain, said: “Many of the top 25 biosimilar manufacturers have an established base in the market, having marketed products for the past five to ten years. However, many will see their position challenged in the coming decade. Rapid growth forecast for the biosimilars market has made it an attractive prospect and many new companies are looking to enter.
“To retain market share, current leaders will launch new biosimilars in the next few years, focusing particularly on monoclonal antibodies (mAbs). Licensing deals will extend the pipelines of established players and new market entrants. Eight of Hospira’s eleven pipeline biosimilars are from its licensing agreement with Celltrion, for example. More deals are expected in this sector in the near future as companies look for a foothold in this fast-growing market.”
Visiongain’s study forecasts biosimilar revenues to 2022 for eight of the leading companies. Two established market players will achieve biosimilar revenue over $2bn by 2022. Dr. Reddy’s will experience the fastest revenue growth in the period, with a CAGR of over 30%. The launch of seven new biosimilars between 2012 and 2018 will stimulate this growth.
Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022 shows analyses of the leading companies in this market. The report provides discussion of portfolio and pipeline products, as well as SWOT analysis, for each. It adds to visiongain’s range of Pharma Leader Series reports, assessing the prospects of leading companies in important pharmaceutical sectors. Visiongain is a business information provider based in London, UK.
For further information concerning the Visiongain’s Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022 report please visit http://www.visiongain.com/Report/906/Pharma-Leader-Series-Top-25-Biosimilar-Drug-Manufacturers-2012-2022
Contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Richard Lang, a pharmaceutical industry analyst for visiongain, said: “Many of the top 25 biosimilar manufacturers have an established base in the market, having marketed products for the past five to ten years. However, many will see their position challenged in the coming decade. Rapid growth forecast for the biosimilars market has made it an attractive prospect and many new companies are looking to enter.
“To retain market share, current leaders will launch new biosimilars in the next few years, focusing particularly on monoclonal antibodies (mAbs). Licensing deals will extend the pipelines of established players and new market entrants. Eight of Hospira’s eleven pipeline biosimilars are from its licensing agreement with Celltrion, for example. More deals are expected in this sector in the near future as companies look for a foothold in this fast-growing market.”
Visiongain’s study forecasts biosimilar revenues to 2022 for eight of the leading companies. Two established market players will achieve biosimilar revenue over $2bn by 2022. Dr. Reddy’s will experience the fastest revenue growth in the period, with a CAGR of over 30%. The launch of seven new biosimilars between 2012 and 2018 will stimulate this growth.
Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022 shows analyses of the leading companies in this market. The report provides discussion of portfolio and pipeline products, as well as SWOT analysis, for each. It adds to visiongain’s range of Pharma Leader Series reports, assessing the prospects of leading companies in important pharmaceutical sectors. Visiongain is a business information provider based in London, UK.
For further information concerning the Visiongain’s Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022 report please visit http://www.visiongain.com/Report/906/Pharma-Leader-Series-Top-25-Biosimilar-Drug-Manufacturers-2012-2022
Contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Contact
Visiongain
Sara Peerun
+44 020 7336 6100
www.visiongain.com
Sara Peerun
+44 020 7336 6100
www.visiongain.com
Contact
Categories